ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
CytomX delivers a pancreatic surprise
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
